| Year |
Citation |
Score |
| 2019 |
van der Heijde D, Strand V, Tanaka Y, Keystone E, Kremer J, Zerbini CAF, Cardiel MH, Stanley Cohen S, Nash P, Song YW, Tegzová D, Gruben D, Wallenstein G, Connell CA, Fleischmann R, et al. Tofacitinib in Combination with Methotrexate in Patients with Rheumatoid Arthritis: Clinical Efficacy, Radiographic and Safety Outcomes from the 24-Month Phase 3 ORAL Scan Study. Arthritis & Rheumatology (Hoboken, N.J.). PMID 30666826 DOI: 10.1002/Art.40803 |
0.361 |
|
| 2018 |
Olsen IC, Lie E, Vasilescu R, Wallenstein G, Strengholt S, Kvien TK. Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry. Rheumatology (Oxford, England). PMID 30508189 DOI: 10.1093/Rheumatology/Key338 |
0.327 |
|
| 2018 |
Strand V, Mysler E, Moots RJ, Wallenstein G, DeMasi R, Gruben D, Soma K, Iikuni N, Fleischmann R. SAT0256 Tofacitinib with and without methotrexate versus adalimumab with methotrexate for the treatment of rheumatoid arthritis: patient-reported outcomes from a phase 3b/4 randomised trial Annals of the Rheumatic Diseases. 77: 990-991. DOI: 10.1136/Annrheumdis-2018-Eular.1312 |
0.324 |
|
| 2017 |
Bergrath E, Gerber RA, Gruben D, Lukic T, Makin C, Wallenstein G. Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis. International Journal of Rheumatology. 2017: 8417249. PMID 28377787 DOI: 10.1155/2017/8417249 |
0.364 |
|
| 2017 |
Schulze-Koops H, Strand V, Nduaka C, DeMasi R, Wallenstein G, Kwok K, Wang L. Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies. Rheumatology (Oxford, England). 56: 46-57. PMID 28028154 DOI: 10.1093/Rheumatology/Kew329 |
0.342 |
|
| 2016 |
Strand V, Lee EB, Fleischmann R, Alten RE, Koncz T, Zwillich SH, Gruben D, Wilkinson B, Krishnaswami S, Wallenstein G. Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial. Rmd Open. 2: e000308. PMID 27752357 DOI: 10.1136/Rmdopen-2016-000308 |
0.33 |
|
| 2016 |
Claxton L, Jenks M, Taylor M, Wallenstein G, Mendelsohn AM, Bourret JA, Singh A, Moynagh D, Gerber RA. An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States. Journal of Managed Care & Specialty Pharmacy. 22: 1088-102. PMID 27579831 DOI: 10.18553/Jmcp.2016.22.9.1088 |
0.321 |
|
| 2016 |
Fleischmann R, Kremer J, Tanaka Y, Gruben D, Kanik K, Koncz T, Krishnaswami S, Wallenstein G, Wilkinson B, Zwillich SH, Keystone E. Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies. International Journal of Rheumatic Diseases. PMID 27451980 DOI: 10.1111/1756-185X.12901 |
0.354 |
|
| 2016 |
Strand V, van Vollenhoven RF, Lee EB, Fleischmann R, Zwillich SH, Gruben D, Koncz T, Wilkinson B, Wallenstein G. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis. Rheumatology (Oxford, England). PMID 26929445 DOI: 10.1093/Rheumatology/Kev442 |
0.337 |
|
| 2016 |
Bergrath E, Wallenstein G, Gerbert R, Gruben D, Makin C. SAT0165 Tofacitinib versus Biologic Treatments in Moderate To Severe Rheumatoid Arthritis Patients Who Have Had An Inadequate Response To Nonbiologic Dmards: Systematic Literature Review and Network Meta-Analysis Annals of the Rheumatic Diseases. 75: 726-726. DOI: 10.1136/Annrheumdis-2016-Eular.4456 |
0.373 |
|
| 2015 |
Strand V, Kremer J, Wallenstein G, Kanik KS, Connell C, Gruben D, Zwillich SH, Fleischmann R. Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs. Arthritis Research & Therapy. 17: 307. PMID 26530039 DOI: 10.1186/S13075-015-0825-9 |
0.364 |
|
| 2015 |
Woolcott JC, Blackhouse G, Claxton L, Wallenstein G, Tran T, Goeree R, Taylor M, Moynagh D, Singh A. SAT0348 The Economic Value of Tofacitinib 5 Mg Bid in the Treatment of Moderate to Severe Rheumatoid Arthritis: A Canadian Analysis Annals of the Rheumatic Diseases. 74: 785-785. DOI: 10.1136/Annrheumdis-2015-Eular.4246 |
0.335 |
|
| 2015 |
Claxton L, Taylor M, Moynagh D, Gruben D, Wallenstein G, Singh A. THU0343 Modelling the Costs and Outcomes Associated with Sequence of Treatment with and Without Tofacitinib for the Treatment of Moderate to Severe Rheumatoid Arthritis in the US Annals of the Rheumatic Diseases. 74: 319-320. DOI: 10.1136/Annrheumdis-2015-Eular.3935 |
0.334 |
|
| 2015 |
Harnett J, Gerber R, Gruben D, Wiederkehr D, Mahgoub EY, Wallenstein G, Koenig A. AB0275 One-Year Treatment Patterns and Healthcare Resource Use Among Patients with Rheumatoid Arthritis Newly Initiating Treatment with Biologic Dmards Annals of the Rheumatic Diseases. 74. DOI: 10.1136/Annrheumdis-2015-Eular.3650 |
0.303 |
|
| 2014 |
Alten R, Strand V, Fleischmann R, Koncz T, Zwillich S, Bradley J, Gruben D, Wilkinson B, Krishnaswami S, Wallenstein G. OP0152 Effects of Tofacitinib Monotherapy versus Methotrexate on Patient-Reported Outcomes in the 2-Year Phase 3 Oral Start TRIAL in Methotrexate-NaÏVe Patients with Rheumatoid Arthritis Annals of the Rheumatic Diseases. 73: 118-119. DOI: 10.1136/Annrheumdis-2014-Eular.3168 |
0.369 |
|
| 2014 |
Rendas-Baum R, Kosinski M, Singh A, Mebus C, Wilkinson B, Riese R, Wallenstein G. FRI0178 Estimated Medical Expenditures among Patients with Rheumatoid Arthritis Undergoing Treatment with Tofacitinib, an Oral Janus Kinase Inhibitor Annals of the Rheumatic Diseases. 73: 446-446. DOI: 10.1136/Annrheumdis-2014-Eular.2476 |
0.34 |
|
| 2013 |
Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, Isaacs JD, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Riese R, Bradley J. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Annals of Internal Medicine. 159: 253-61. PMID 24026258 DOI: 10.7326/0003-4819-159-4-201308200-00006 |
0.361 |
|
| 2013 |
van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, Cardiel MH, Cohen S, Nash P, Song YW, Tegzová D, Wyman BT, Gruben D, Benda B, Wallenstein G, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis and Rheumatism. 65: 559-70. PMID 23348607 DOI: 10.1002/Art.37816 |
0.336 |
|
| 2013 |
Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Soma K, Bradley J, Mebus C. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 381: 451-60. PMID 23294500 DOI: 10.1016/S0140-6736(12)61424-X |
0.359 |
|
| 2013 |
Strand V, Fleischmann R, Alten RE, Koncz T, Zwillich SH, Bradley JD, Gruben D, Wilkinson B, Krishaswami S, Wallenstein G. THU0258 Oral Start: Effects of the Oral JAK Inhibitor Tofacitinib Monotherapy Versus Methotrexate on Patient-Reported Outcomes in the Phase 3 Oral Start Trial of Active Rheumatoid Arthritis Annals of the Rheumatic Diseases. 72. DOI: 10.1136/Annrheumdis-2013-Eular.786 |
0.367 |
|
| 2013 |
Schulze-Koops H, Benda B, Wallenstein G, Riese R, Zwillich SH, Kwok K, Wang L, Bradley J. THU0241 Haemoglobin Changes and Relationship between Anaemia and Fatigue or Vitality in Rheumatoid Arthritis Patients Treated with Tofacitinib Annals of the Rheumatic Diseases. 72. DOI: 10.1136/Annrheumdis-2013-Eular.769 |
0.343 |
|
| 2013 |
Keystone E, Fleischmann R, Vollenhoven Rv, Kremer J, Gruben D, Bradley J, Riese R, Mebus C, Wallenstein G, Zwillich SH, Benda B, Krishnaswami S. THU0228 Tofacitinib, an Oral Janus Kinase Inhibitor: Post-HOC Analyses of Efficacy and Safety of Monotherapy Versus Combination Therapy in a Phase 3 Rheumatoid Arthritis Population Annals of the Rheumatic Diseases. 72. DOI: 10.1136/Annrheumdis-2013-Eular.756 |
0.326 |
|
| 2013 |
Vieira MC, Wallenstein G, Bradley J, Gruben D, Koncz T, Zwillich SH, Jansen JP. SAT0115 Tofacitinib Versus Biologic Treatments in Patients with Active Rheumatoid Arthritis Who have had an Inadequate Response to Tumour Necrosis Factor Inhibitors - A Network Meta-Analysis Annals of the Rheumatic Diseases. 72. DOI: 10.1136/Annrheumdis-2013-Eular.1841 |
0.318 |
|
| 2013 |
Vollenhoven RFv, Wallenstein G, Lee EB, Fleischmann R, Zwillich SH, Gruben D, Koncz T, Bradley J, Wilkinson B, Strand V. THU0151 Effects of tofacitinib (CP-690,550), an oral janus kinase inhibitor, or adalimumab on patient reported outcomes in a phase 3 study of active rheumatoid arthritis Annals of the Rheumatic Diseases. 71: 206-206. DOI: 10.1136/Annrheumdis-2012-Eular.2116 |
0.366 |
|
| 2012 |
Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, Gruben D, Kanik KS, Krishnaswami S, Pascual-Ramos V, Wallenstein G, Zwillich SH. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis and Rheumatism. 64: 970-81. PMID 22006202 DOI: 10.1002/Art.33419 |
0.347 |
|
| 2012 |
Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadis S, Connell CA, Gruben D, Krishnaswami S, Wallenstein G, Wilkinson BE, Zwillich SH. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis and Rheumatism. 64: 617-29. PMID 21952978 DOI: 10.1002/Art.33383 |
0.356 |
|
| 2011 |
Michaud K, Wallenstein G, Wolfe F. Treatment and nontreatment predictors of health assessment questionnaire disability progression in rheumatoid arthritis: a longitudinal study of 18,485 patients. Arthritis Care & Research. 63: 366-72. PMID 21080449 DOI: 10.1002/Acr.20405 |
0.33 |
|
| 2011 |
Heijde DVd, Tanaka Y, Fleischmann R, Keystone EC, Kremer JM, Zerbini CAF, Cardiel M, Cohen SB, Nash PT, Song YW, Tegzova D, Wyman B, Gruben D, Benda B, Wallenstein G, et al. Tofacitinib (CP-690,550), an oral janus kinase inhibitor, in combination with methotrexate reduced the progression of structural damage in patients with rheumatoid arthritis: A 24-Month Phase 3 Study Arthritis & Rheumatism. 63. DOI: 10.1002/Art.33310 |
0.315 |
|
| 2002 |
Wallenstein GV, Vago DR, Walberer AM. Time-dependent involvement of PKA/PKC in contextual memory consolidation. Behavioural Brain Research. 133: 159-64. PMID 12110449 DOI: 10.1016/S0166-4328(01)00476-4 |
0.609 |
|
| 2001 |
Wallenstein GV, Vago DR. Intrahippocampal scopolamine impairs both acquisition and consolidation of contextual fear conditioning. Neurobiology of Learning and Memory. 75: 245-52. PMID 11300731 DOI: 10.1006/Nlme.2001.4005 |
0.607 |
|
| 2000 |
Kesner RP, Gilbert PE, Wallenstein GV. Testing neural network models of memory with behavioral experiments. Current Opinion in Neurobiology. 10: 260-5. PMID 10753789 DOI: 10.1016/S0959-4388(00)00067-2 |
0.465 |
|
| 2000 |
McCarley R, Kwon J, O’Donnell B, Wallenstein G, Greene R, Hirayasu Y, Nestor P, Hasselmo M, Shenton M. 569. Gamma frequency auditory processing abnormalities in schizophrenia Biological Psychiatry. 47: S173. DOI: 10.1016/S0006-3223(00)00881-7 |
0.385 |
|
| 1999 |
Kwon JS, O'Donnell BF, Wallenstein GV, Greene RW, Hirayasu Y, Nestor PG, Hasselmo ME, Potts GF, Shenton ME, McCarley RW. Gamma frequency-range abnormalities to auditory stimulation in schizophrenia. Archives of General Psychiatry. 56: 1001-5. PMID 10565499 DOI: 10.1001/Archpsyc.56.11.1001 |
0.443 |
|
| 1999 |
Fransén E, Wallenstein GV, Alonso AA, Dickson CT, Hasselmo ME. A biophysical simulation of intrinsic and network properties of entorhinal cortex Neurocomputing. 26: 375-380. DOI: 10.1016/S0925-2312(99)00027-2 |
0.433 |
|
| 1998 |
Wallenstein GV, Eichenbaum H, Hasselmo ME. The hippocampus as an associator of discontiguous events. Trends in Neurosciences. 21: 317-23. PMID 9720595 DOI: 10.1016/S0166-2236(97)01220-4 |
0.444 |
|
| 1997 |
Wallenstein GV, Hasselmo ME. Functional transitions between epileptiform-like activity and associative memory in hippocampal region CA3. Brain Research Bulletin. 43: 485-93. PMID 9250622 DOI: 10.1016/S0361-9230(97)00003-8 |
0.471 |
|
| 1997 |
Wallenstein GV, Hasselmo ME. GABAergic modulation of hippocampal population activity: sequence learning, place field development, and the phase precession effect. Journal of Neurophysiology. 78: 393-408. PMID 9242288 DOI: 10.1152/Jn.1997.78.1.393 |
0.455 |
|
| 1996 |
Hasselmo ME, Wyble BP, Wallenstein GV. Encoding and retrieval of episodic memories: role of cholinergic and GABAergic modulation in the hippocampus. Hippocampus. 6: 693-708. PMID 9034856 DOI: 10.1002/(Sici)1098-1063(1996)6:6<693::Aid-Hipo12>3.0.Co;2-W |
0.648 |
|
| 1995 |
Wallenstein GV, Nash AJ, Kelso JA. Frequency and phase characteristics of slow cortical potentials preceding bimanual coordination. Electroencephalography and Clinical Neurophysiology. 94: 50-9. PMID 7530639 DOI: 10.1016/0013-4694(94)00220-F |
0.432 |
|
| 1995 |
Wallenstein GV, Kelso JAS, Bressler SL. Phase transitions in spatiotemporal patterns of brain activity and behavior Physica D: Nonlinear Phenomena. 84: 626-634. DOI: 10.1016/0167-2789(95)00056-A |
0.482 |
|
| Show low-probability matches. |